Alcon (ALC)
(Delayed Data from NYSE)
$92.39 USD
+1.22 (1.34%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $92.89 +0.50 (0.54%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
ALC 92.39 +1.22(1.34%)
Will ALC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALC
McKesson (MCK) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Is Alcon (ALC) Outperforming Other Medical Stocks This Year?
ALC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Alcon (ALC) is a Strong Momentum Stock
Here's Why Alcon (ALC) is a Strong Momentum Stock
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
Other News for ALC
ClearBridge Global Growth Strategy Q2 2024 Commentary
ClearBridge International Growth ACWI Ex-US Strategy Q2 2024 Commentary
Evolus Continues To Make Progress
Algoma Central Corporation Reports Financial Results for the 2024 Second Quarter
Algoma Central Braces for Growth Despite Challenges